-
Oil prices spike on fresh US-Iran attacks, tech weighs on stocks again
-
'Indispensable' Xiaohongshu app fuels Chinese tourism
-
Spaniard's rare skin disorder ups danger of summer heat
-
NFL seeks to break into Africa with Kenya competition
-
Protected but deported anyway, as Trump goes after 'dreamers'
-
Yamal aims to steal Mbappe's World Cup thunder in semi-final showdown
-
Dodgers face Ohtani knee issues in MLB three-peat bid
-
Fisk outlasts Pendrith in playoff to win PGA Tour Louisville title
-
Warriors forward Green details LeBron recruiting pitch
-
US strikes Iran as Gulf states targeted in flareup over Hormuz
-
Massive fire in Bangkok bar kills at least 27
-
'Final before final': France face Spain in World Cup blockbuster
-
Zverev vows to chase down Wimbledon champion Sinner in trophy charge
-
England's Ecclestone glad to get 'one-up' on brother with five-wicket Lord's haul
-
Five classic France v Spain clashes before World Cup semi-final
-
Major fire rages in Fontainebleau forest near Paris
-
World Cup gets set for pair of blockbuster semi-finals
-
Sinner enjoying 'very rare' Wimbledon triumph
-
Venezuela quake death toll rises to 4,490
-
England open door to Flower return after McCullum axed as Test coach
-
McGregor says knee fine before first-kick injury, vows return
-
South Korea's Tom Kim wins Scottish Open to end three-year title drought
-
Hundred heroine Bhatia says its's 'unbelievable' to be on Lord's honours board
-
'It's amazing': Sinner revels in Wimbledon glory after Zverev battle
-
Irrepressible Sinner outlasts Zverev to win second straight Wimbledon title
-
Fresh attacks hit Iran, Kuwait as Tehran and US square off over Hormuz
-
Ryu defeats Henderson in play-off to win back-to-back majors in Evian
-
Argentina football great Rattin dies at 89
-
Spain ex-PM draws criticism with 'xenophobic' remark on French team
-
Argentina great Rattin dies at 89
-
Israel elections to be held on October 27: parliament
-
Bellingham drags England into World Cup semis but Tuchel demands more
-
Zelensky orders new PM in major government reshuffle
-
Pogacar calls for cycling calendar overhaul due to heatwave
-
Van der Poel stays calm in the heat to win Tour de France stage nine
-
Van der Poel wins shortened Tour de France ninth stage
-
Iran declares Hormuz strait closed, US military insists traffic flowing
-
McCullum sacked as England Test coach but retains white-ball role
-
Marc Marquez cruises to Germany MotoGP victory, enters title race
-
Bhatia first woman to score Lord's Test century as India run riot
-
Mladenovic and Guo win Wimbledon women's doubles title
-
'Insane heat': Durbridge calls for earlier Tour de France starts
-
McCullum stands down as England Test cricket coach
-
McCullum stand downs as England Test cricket coach
-
Marc Marquez cruises to Germany MotoGP Grand Prix victory
-
India's Bhatia becomes first woman to score Lord's Test century
-
Ukraine's Zelensky orders government reshuffle, new PM
-
India's Bhatia in sight of becoming first woman to score Lord's Test century
-
Iran, US trade more strikes as fighting escalates
-
Нуша Аубель і Потсдам: довіра втрачена
Study shows how fast kilos return after ending weight-loss drugs
When people stop taking the new generation of weight-loss drugs they pile back on the kilos four times faster than they would after ending diet and exercise regimes, new research found Thursday.
But this was mostly because they lost so much weight in the first place, according to the British researchers who conducted the largest and most up-to-date review of the subject.
A new generation of appetite-suppressing, injectable drugs called GLP-1 agonists have become immensely popular in the last few years, transforming the treatment for obesity and diabetes in many countries.
They have been found to help people lose between 15-20 percent of their body weight.
"This all appears to be a good news story," said Susan Jebb, a public health nutrition scientist at Oxford university and co-author of a new BMJ study.
However, recent data has suggested that "around half of people discontinue these medications within a year," she told a press conference.
This might be because of common side effects such as nausea or the price -- these drugs can cost over $1,000 a month in the US.
So the researchers reviewed 37 studies looking at ceasing different weight-loss drugs, finding that participants regained around 0.4 kilograms a month.
Six of the clinical trials involved semaglutide -- the ingredient used in Novo Nordisk's brands Ozempic and Wegovy -- and tirzepatide used for Eli Lilly's Mounjaro and Zepbound.
While taking these two drugs, the trial participants lost an average of nearly 15 kilograms.
However after stopping the medication, they regained 10 kilograms within a year, which was the longest follow-up period available for these relatively new drugs.
The researchers projected that the participants would return to their original weight in 18 months.
Measurements of heart health, including blood pressure and cholesterol levels, also returned to their original levels after 1.4 years.
People who were instead put on programmes that included diet and exercise -- but not drugs -- lost significantly less weight. However it took an average of four years for them to regain their lost kilos.
This meant that people taking the drugs regained their weight four times faster.
- 'Starting point, not a cure' -
"Greater weight loss tends to result in faster weight regain," lead study author Sam West of Oxford University explained.
But separate analysis showed that weight gain was "consistently faster after medication, regardless of the amount of weight lost in the first place," he added.
This could be because people who have learned to eat more healthily and exercise more often continue to do so even as they regain weight.
Jebb emphasised that GLP-1 drugs "are a really valuable tool in obesity treatment -- but obesity is a chronic relapsing condition."
"One would expect that these treatments need to be continued for life, just in the same way as blood pressure medication," Jebb said.
If this was the case, it would impact how national health systems judge whether these drugs are cost-effective, the researchers emphasised.
"This new data makes it clear they are a starting point, not a cure," said Garron Dodd, a metabolic neuroscience researcher at the University of Melbourne not involved in the study.
"Sustainable treatment will likely require combination approaches, longer-term strategies, and therapies that reshape how the brain interprets energy balance, not just how much people eat," he said.
A.Kunz--VB